Original Publication Date: 1 August, 2014
Publication / Source: Lung Cancer Management
Authors: Olivier Huillard, Cécile Defaucheux, Jeanne Chapron et al
Bevacizumab is an antiangiogenic targeted therapy approved for the treatment of patients with advanced non-small-cell lung cancer other than predominantly squamous cell histology in addition to platinum-based chemotherapy. The safety of bevacizumab has been assessed in studies across most cancer types and bevacizumab is generally well tolerated.